Latest Edge Ai Technology News

Kincora Copper has begun its inaugural basement drilling at the Wongarbon porphyry project, targeting a major gold-copper system supported by NSW government funding and cutting-edge AI technology.

Artrya Limited has expanded its SAPPHIRE clinical study with Ascension, one of the largest US non-profit health systems, joining as the fourth major participant. This move strengthens the study’s reach and advances the evaluation of Artrya’s AI-powered Salix platform for coronary artery disease detection.

BrainChip Holdings Ltd has launched a fully underwritten $35 million placement alongside a $2 million share purchase plan to fund the commercialization of its Akida 2.0 technology and new TENNs product development. The capital raise underscores the company’s commitment to expanding its footprint in the rapidly growing edge AI market.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

BrainChip Holdings Ltd showcased its leadership in ultra-low-power edge AI technology, emphasizing strong partnerships and a growing product portfolio targeting high-growth sectors like defense and healthcare.

dorsaVi has confirmed its RRAM Reflex Platform achieves biological-grade reflexes with sub-microsecond latency and ultra-low energy use, outperforming leading digital edge AI systems by orders of magnitude.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.

BrainChip Holdings reported a solid June quarter with $13.5 million in cash, increased customer inflows, and a strategic decision to remain listed on the ASX. The company advanced multiple commercial collaborations and expanded its intellectual property portfolio, signaling confidence in its edge AI technology roadmap.

BlinkLab has expanded its pivotal FDA autism diagnostic trial by adding the University of Nebraska Medical Center as a second U.S. clinical site, advancing toward broader validation and regulatory clearance.

Codeifai Limited has confirmed entering a binding agreement to acquire the QuantumAI Secure platform from Credissential Inc, affirming its compliance with ASX continuous disclosure rules amid regulatory scrutiny.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

BrainChip Holdings Ltd’s 2025 AGM reveals a strengthened product roadmap, breakthrough Edge AI technology advances, and a surge in commercial partnerships, positioning the company for accelerated growth.